Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 25 mg - tablet, uncoated - excipient ingredients: wheat starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; povidone - suppression of voluntary muscle spasm in: *multiple sclerosis, *spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: - skeletal hypertonus - spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 25 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; wheat starch; microcrystalline cellulose; magnesium stearate; povidone - suppression of voluntary muscle spasm in: *multiple sclerosis, *spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: - skeletal hypertonus - spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 10 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; wheat starch - suppression of voluntary muscle spasm in: *multiple sclerosis, *spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: - skeletal hypertonus - spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - baclofen, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; povidone; colloidal anhydrous silica; magnesium stearate - suppression of voluntary muscle spasm in: multiple sclerosis; spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing skeletal hypertonus, spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - baclofen, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; povidone; colloidal anhydrous silica; magnesium stearate - suppression of voluntary muscle spasm in: multiple sclerosis; spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing skeletal hypertonus, spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - baclofen, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch - suppression of voluntary muscle spasm in: multiple sclerosis; spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing skeletal hypertonus and spastic and dyssynergic bladder dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - baclofen, quantity: 25 mg - tablet - excipient ingredients: maize starch; microcrystalline cellulose; lactose monohydrate; magnesium stearate - suppression of voluntary muscle spasm in: multiple sclerosis; spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing skeletal hypertonus and spastic and dyssynergic bladder dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - baclofen, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; calcium hydrogen phosphate; colloidal anhydrous silica; sodium starch glycollate; magnesium stearate - the suppression of voluntary muscle spasm in: multiple sclerosis, spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: skeletal hypertonus, spastic and dyssynergic bladder dysfunction. baclofen is not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - baclofen, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; sodium starch glycollate; lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - the suppression of voluntary muscle spasm in: multiple sclerosis, spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: skeletal hypertonus, spastic and dyssynergic bladder dysfunction. baclofen is not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - baclofen, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; povidone; colloidal anhydrous silica; magnesium stearate - suppression of voluntary muscle spasm in: multiple sclerosis; spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing skeletal hypertonus, spastic and dyssynergic bladder dysfunction. not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.